SCHOLAR ROCK HOLDING CORPORATION (SRRK) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$108.90M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$102.02M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$103.55M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$112.11M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$108.90M | (m) | $0.00* | (m) | $1.00K* | -$70.31M* | (m) | $58.23M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$102.02M | (m) | $0.00 | (m) | $68.00K | -$82.10M | (m) | $51.81M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$103.55M | (m) | $0.00* | (m) | $84.00K* | -$68.92M* | (m) | $50.49M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$112.11M | (m) | (m) | (m) | $215.00K* | -$76.94M* | (m) | $62.40M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$77.09M | (m) | (m) | (m) | $271.00K | -$78.67M | (m) | $48.68M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$64.78M | (m) | (m) | (m) | $31.00K* | -$52.45M* | (m) | $48.72M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$59.50M | (m) | (m) | (m) | $22.00K* | -$49.20M* | (m) | $42.37M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$58.42M | (m) | (m) | (m) | $23.00K | -$49.78M | (m) | $43.09M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$43.67M | (m) | (m) | (m) | $0.00* | -$32.27M* | (m) | $30.34M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$39.08M | (m) | (m) | (m) | $41.00K* | -$32.55M* | (m) | $26.87M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$40.51M | (m) | (m) | (m) | $30.00K | -$43.05M | (m) | $29.73M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$43.86M | (m) | $0.00* | (m) | $27.00K* | -$26.48M* | (m) | $33.39M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$43.15M | (m) | $0.00* | (m) | $477.00K* | -$34.74M* | (m) | $32.07M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$6.93M | (m) | $33.19M | (m) | $443.00K | -$42.56M | (m) | $29.37M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$37.08M | (m) | $5.46M | (m) | $1.41M* | -$35.98M* | (m) | $31.27M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$30.27M | (m) | $4.59M | (m) | $983.00K* | -$31.81M* | (m) | $25.60M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$27.21M | (m) | $4.71M | (m) | $2.31M | -$26.54M | (m) | $22.55M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$23.62M | (m) | $3.04M | (m) | $1.83M* | -$23.39M* | (m) | $18.38M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$19.46M | (m) | $3.90M | (m) | $74.00K* | -$19.83M* | (m) | $17.00M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$17.69M | (m) | $5.03M | (m) | $209.00K | $2.64M | (m) | $16.90M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$17.11M | (m) | $4.77M | (m) | $366.00K* | -$15.11M* | (m) | $15.70M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$13.39M | (m) | $5.04M | (m) | $598.00K* | -$16.41M* | (m) | $13.71M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$11.70M | (m) | $3.11M | (m) | $681.00K | -$15.53M | (m) | $10.74M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$11.23M | (m) | $0.00 | (m) | $599.00K* | -$9.01M* | (m) | $8.06M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$14.88M | (m) | $0.00 | (m) | $16.00K* | -$11.63M* | (m) | $11.42M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$9.02M | (m) | (m) | (m) | $176.00K | -$9.88M | (m) | $6.70M | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$5.94M | (m) | $0.00 | (m) | $38.00K* | -$5.75M* | (m) | $4.78M | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$5.89M | (m) | $0.00 | (m) | (m) | (m) | (m) | $4.71M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$384.64M | (m) | $0.00 | (m) | $602.00K | -$300.04M | (m) | $208.44M | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$252.05M | (m) | (m) | (m) | $98.00K | -$200.95M | (m) | $184.55M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$171.29M | (m) | (m) | (m) | $71.00K | -$145.23M | (m) | $121.90M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$134.37M | (m) | $33.19M | (m) | $1.06M | -$132.69M | (m) | $124.44M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$129.92M | (m) | $18.82M | (m) | $5.25M | -$126.79M | (m) | $108.47M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$86.88M | (m) | $15.40M | (m) | $4.09M | -$60.27M | (m) | $74.06M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$54.54M | (m) | $20.49M | (m) | $3.12M | -$63.12M | (m) | $54.22M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$50.69M | (m) | (m) | (m) | $1.49M | $24.57M | (m) | $36.31M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$25.03M | (m) | (m) | (m) | $361.00K | -$21.74M | (m) | $19.94M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |